Cardiovascular disease drugs in development intended to reduce lipoprotein (a) are mostly injectable medications, though Eli Lilly also has both oral and injectable drugs in the clinic. AstraZeneca aims to hit that key protein target with an oral small molecule licensed from CSPC Pharmaceutical Group.
The post AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for Oral Way to Drug Lp(a) appeared first on MedCity News.
